

# JTK-853

Catalog No: tcsc0016935



## Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg



## Specifications

### CAS No:

954389-09-4

### Formula:

$C_{28}H_{23}F_7N_6O_4S_2$

### Pathway:

Anti-infection

### Target:

HCV

### Purity / Grade:

>98%

### Solubility:

10 mM in DMSO

### Observed Molecular Weight:

704.64


## Product Description

JTK-853 is a novel, non-nucleoside **Hepatitis C Virus (HCV) polymerase** inhibitor which shows effective antiviral activity in **HCV replicon** cells with **EC<sub>50</sub>**s of 0.38 and 0.035  $\mu$ M in genotype 1a H77 and 1b Con1 strains, respectively.

IC50 & Target: HCV polymerase<sup>[1]</sup>

EC50: 0.38  $\mu$ M (1a H77 HCV), 0.035  $\mu$ M (1b Con1 HCV)<sup>[1]</sup>

***In Vitro:*** JTK-853 is a novel, non-nucleoside Hepatitis C Virus Polymerase inhibitor which shows effective antiviral activity in HCV replicon cells with EC<sub>50</sub>s of 0.38 and 0.035  $\mu$ M in genotype 1a H77 and 1b Con1 strains, respectively. When JTK-853 is incubated with the replicon cells for 48 h, it shows antiviral activity against genotype 1a H77 and 1b Con1 replicon cells with EC<sub>90</sub> values of 6.5 $\pm$ 0.5 and 0.34 $\pm$ 0.05  $\mu$ M, respectively. At 10  $\mu$ M, JTK-853 induces apparent Huh-7.5 cell death in 2-week culture. JTK-853 suppresses the drug-resistant colony formation in the genotype 1a replicon cells, and the numbers of JTK-853-resistant colonies are much lower than those of GS-9190-resistant colonies for both genotypes<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!